Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What was the follow-up time on Prurisol? and how long does it take to unblind B-OM and report?
Oils hot, Brent flirting with $60 which is where I think Holloman said they would look at work it again, before they hibernated. If it could stabilize here, could see something in a few months.
I guess the last patient for follow-up is next week, good to know. I was wondering what the timeline was.
I received an email from Leo today, he remains very optimistic that upcoming trial results will correct the share price. I had expressed my frustration with the market cap over the last several years but remained hopeful for the future. I had asked about artificial ways to increase SP.
He means an endorsement from any Big Tobacco company.
IPIX trades in the sewer only because of the exchange that it is on. Leo seems confident that the SP will eventually reflect company achievements/milestones so he can up-list. I'm having my doubts. I would suffer a few weeks of downtrend that comes with a R/S to get this on the road at this point.
There is an informative article on S.A. this morning about four of the company patents. Worth a read.
I don't follow this often, and my memory is short but I believe end of year something is due.
I see no reason why the value is lower now than 2 years ago. This could go from $.025 to $.20 overnight with just news indicating that they haven't abandoned the investment.
Despite what hwpbnj says I think you are spot on with that. Originally I was 3$ or under, but I think 2.50$ is the best target for the bottom right now. This is definitely a dip from the run, I see no reason that it won't continue. Another week or so to what could be a nice catalyst as well.
22nd Century Group Could Win Big From FDA Plan To Reduce Nicotine In Cigarettes
SA Article. Writer has a strong following.
Been a long time since I looked at this after I cut my losses a long time ago. You were right the whole time, good on you. All the bashing you took... just stay away from the other one. Thanks!
Last I remember Leo mentioning about K was that the oral formulation is what BP was interested most in. I think the next big step with K will be the oral formulation and not so much the ongoing trial, which if I recall correctly they want to finish the trial with? (Someone correct me if I'm wrong).
Obviously the drug as is should be drawing attention, but I distinctly remember Leo saying oral is what BP wants to see.
Wish it was more, still only about 6%. See a lot of good stocks with 30%+.
I'm as long as I'm getting unless it drops below 1$. Let's gogo!
There are no sellers right now of any real size. I've had a 8K bid in at 0.78 for an hour.
For me... I've been wanting it to continue lower. I am a shareholder... red obviously, but nothing has changed here.
Good call man, props.
I'm lucky enough to be sitting in an airport, delayed several hours and can't listen. Looking forward to the highlights and/or transcript.
If history tells us anything, I doubt it will have much effect. The first major SP increase will come from a partnership, at which point things will really get moving.
I'm not saying that this would happen, it is just since I was invested in another company that did it I worry.
With this other company, SP was over $3.00 (250M$ MC) and gradually faded to under a dime while construction was ongoing. The company said that the companies MC did not reflect the value of the company, so turned it private and compensated SH by paying the MA over the past month or something, which was in the pennies.
Unrealised losses and the hopes of gains vanished.
It would go to 0, shareholders may be compensated in some minor way.
Oh wow, the man returns. :)
Tell us the word my man, what is written?
Oil prices to low to do anything before deadlines as they said. I think my only real concern is that they turn the company private. Have seen that happen before...
Oh wow, the man returns. :)
Tell us the word my man, what is written?
Oil prices to low to do anything before deadlines as they said. I think my only real concern is that they turn the company private. Have seen that happen before...
I have heard a lot about naked positions having to close before with CUSIP changes. Do you know this for sure (by Tuesday)? Every other time I have seen it with other stocks it equated to nothing and to be incorrect.
22nd Century and Dent Neurosciences Research Center to Partner on Brain Imaging Clinical Trial
Trial will image brain activity associated with smoking Company’s proprietary Very Low Nicotine cigarettes
June 08, 2017 09:20 AM Eastern Daylight Time
CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that it has signed a collaborative research agreement with The Dent Neurosciences Research Center. The agreement features a clinical trial that will use functional magnetic resonance imaging (fMRI) to image the brains of smokers. Participants will smoke 22nd Century’s proprietary Very Low Nicotine (VLN) cigarettes, or conventional cigarettes, which will allow scientists to study both the immediate and longer-term effects of nicotine on brain activity.
“The identification of changes in brain activity associated with smoking our VLN cigarettes compared to smoking regular cigarettes will be an important step forward”
Tweet this
Recent clinical trial findings suggest that a significant physiological change occurs in the brains of smokers as early as 6 days after switching to Very Low Nicotine cigarettes (Donny et al., 2015; Mercincavage et al., 2016). Over the course of the Dent trial, researchers will study changes in the physiology of the brains of VLN smokers. As a result, scientists hope to identify changes in the brain that correlate with changes in nicotine addiction. A non-invasive marker of addiction status at the level of brain activity would be an invaluable tool for future studies on nicotine addiction.
The differences in brain activity after smoking a single VLN cigarette as opposed to smoking a conventional cigarette will provide 22nd Century scientists with important insights into the mechanisms of how the Company’s proprietary VLN cigarettes affect the physiology of smokers’ brains.
“The identification of changes in brain activity associated with smoking our VLN cigarettes compared to smoking regular cigarettes will be an important step forward,” explained Dr. Paul Rushton, 22nd Century’s Vice President for Plant Biotechnology.
“Clinical trials show that 22nd Century’s Very Low Nicotine SPECTRUM® cigarettes are associated with significant reductions in consumption and increases in quit attempts,” explained Dr. Laszlo Mechtler, Medical Director at The Dent Neurosciences Research Center. “We are very excited that this project will study the brain’s response to Very Low Nicotine cigarettes and may identify exactly how Very Low Nicotine cigarettes work to alter behavior in smokers.”
Does XXII usually live stream the calls? If so, does anyone have a link?
Thanks,
Probably because people complain when he gives us updates, then when he doesn't, they do as well. He can't win.
People on this board are way to overcritical of LE. He has done a fine job, in no way is the current SP his fault.
Additionally, this is an OTC stock... if you can't handle major swings, look on a major exchange.
Everyone of the companies milestones have been met so far this year.
The PR states that it will be posted at 1100EST, not quite there yet.
I don't recall ever hearing anything about an oral pill for ABSSSI. Besides efficacy, the single IV dose was the major draw here right?
The rest of the article is just ... nothing.
I like that it did not instantly sell back down this morning, even the bid is creeping up.
Even at $0.07 the company is still valued at approx. 8 million, far under what it could/should be at this time even without proven reserves or active wells.
Deadly fungal infection that doctors have been fearing now reported in U.S.
http://www.msn.com/en-ca/news/world/deadly-fungal-infection-that-doctors-have-been-fearing-now-reported-in-us/ar-AAo6ZXk?li=AAggNb9&ocid=iehp
If there is ever a lawsuit, I want in. Glad I got out a while ago, still lost tens of thousands.
I took a look at PCYC - Ibrutinib today, the numbers were much higher than I expect.
In 2011 after Phase2, Johnson and Johnson partnered with them for $150M upfront and $825M in milestones. Rather large numbers for a drug with so many side effects.
Sold in 2015 for $21B (including pipeline) to Abbvie, I didn't even consider before that a company could/would sell to a different company than a partner.
Makes me wonder what a competitor might offer for a partnership for a more efficacious drug with less side effects.
The 10-K and conference call should be coming very shortly right? Last year it was 18 and 11 Feb respectively.
Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer
Cellceutix Corporation:
A small mid-stage study is being initiated at a Texas cancer center which is designed to evaluate Kevetrin for safety, tolerability, as well as assess changes in select biomarkers and objective tumor response. Cellceutix believes that this clinical trial, using IV dosing, will directly inform how Kevetrin modulates the p53 signaling pathway—one of the key questions asked by pharmaceutical companies under Confidential Disclosure Agreement (CDA). Furthermore, as the Company has recently achieved 79 percent bioavailability of Kevetrin by oral administration in animal testing, Cellceutix anticipates being able to subsequently switch to oral dosing in future clinical trials, resulting in more frequent and convenient drug delivery. Bridging toxicology studies are now underway to enable this transition to oral dosing of patients.
The trial, we will be using sophisticated molecular mapping technology to analyze ovarian cancer tissue samples removed from study participants. Such data, complementing that already generated by testing discrete ovarian cancer cell-lines, will anchor Cellceutix’s understanding of Kevetrin’s multimodal mechanism of action, providing a more complete understanding of its full potential as a novel cancer treatment.
About Cellceutix Phase 2a Ovarian Cancer Trial Design
CTIX-KEV-201 is an open-label, Phase 2a study evaluating the safety, tolerability, and pharmacokinetics of Kevetrin as well as changes in select biomarkers and objective tumor response when administered to patients with platinum-resistant/refractory ovarian cancer. The clinical trial comprises two different short-term treatment regimens and will enroll an estimated 10 patients. Primary outcome measures include the incidence of Treatment-Emergent Adverse Events (TEAEs) and changes in pre-specified biomarkers (via tumor biopsy, examination of ascites fluid and peripheral blood), pre-treatment and post-treatment, at 3 weeks. Secondary outcome measures include objective tumor response, per Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) and plasma concentrations of Kevetrin.
For more information on the CTIX-KEV-201 Phase 2a study, please visit:
https://clinicaltrials.gov/ct2/show/NCT03042702
The above information is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
2
The information presented in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
A WARNING ABOUT FORWARD-LOOKING STATEMENTS:
The information contained herein contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Anyone on this board doing the selling today? -- Would be nice to get some kind of update from the company. I tried emailing the majority of the people involved with the company and got no response at all. These Holloman guys have little idea, or perhaps experience in how to run a public company.
People thought that about them at $7 as well. The truth is hard for investors to digest. Management lined their pockets at the expense of shareholders.
Perhaps I am misreading the PR, but I read this as having nothing to do with the X-22 discussions with the FDA for the NDA. Are the MRTPA's and PMTA's from BRAND A linked directly to the X-22 decision for the NDA application? I thought that the X-22 decision from the FDA is what people were waiting for in/by March?
I need glasses.
Did they say that? Haven't seen a PR and volume doesn't indicate that.
I realized it was an old well being sidetracked but wasn't sure if the news about the miss was new or not. I'm still a little confused so just going to wait for the news from Claren next week.
Thanks for the article.